诺诚健华制药有限公司 - 收益表 (TTM)

诺诚健华制药有限公司
HK ˙ SEHK ˙ KYG4783B1032
HK$17.70 ↑0.27 (1.55%)
2025-09-05
分享价格
收益表 (TTM)

诺诚健华制药有限公司 损益表显示一段时间内收入和支出的变化。损益表数据包括销售和收入、毛利、研发、销售、一般和管理费用、经营收入、所得税费用、利息费用、营业外收入、每股收益和已发行股票。

除每股单位外,所有数字都是 1,000,000。

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
收入 1 1 52 102 982 1,043 1,111 1,187 503 625 696 757 721 739 715 781 899 1,009 1,225 1,321
改变 (%) -6.83 3,699.01 97.37 859.92 6.24 6.55 6.84 -57.62 24.28 11.24 8.82 -4.73 2.41 -3.19 9.20 15.14 12.30 21.34 7.86
收入百分比 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
销售成本 5 10 38 66 89 119 127 143 158 157 145 128 110 113 126 138 150 155
改变 (%) 100.00 286.50 72.95 36.15 32.63 7.45 12.54 9.93 -0.58 -7.77 -11.15 -14.49 2.43 11.63 10.24 8.51 3.19
收入百分比 9.48 9.61 3.87 6.30 8.05 9.99 25.32 22.93 22.66 20.70 20.05 17.39 15.36 14.41 13.97 13.71 12.26 11.73
毛营业利润 1 1 47 92 944 977 1,022 1,069 376 482 538 600 577 610 605 668 773 871 1,075 1,166
改变 (%) -6.83 3,338.89 97.09 920.85 3.56 4.56 4.58 -64.84 28.26 11.62 11.57 -3.94 5.81 -0.81 10.42 15.73 12.63 23.38 8.51
收入百分比 100.00 100.00 90.52 90.39 96.13 93.70 91.95 90.01 74.68 77.07 77.34 79.30 79.95 82.61 84.64 85.59 86.03 86.29 87.74 88.27
销售、一般及行政费用 131 158 222 286 337 437 475 516 562 613 606 625 597 551 560 520 557 590 615 675
改变 (%) 20.72 40.78 28.97 17.82 29.61 8.81 8.55 8.96 9.06 -1.22 3.14 -4.42 -7.69 1.64 -7.25 7.08 6.02 4.17 9.79
收入百分比 8,916.09 11,552.71 428.11 279.74 34.34 41.89 42.78 43.46 111.75 98.06 87.08 82.54 82.81 74.65 78.37 66.57 61.91 58.45 50.17 51.07
研发 382 403 380 356 678 722 759 815 605 639 651 722 714 757 794 817 823 815 844 843
改变 (%) 5.34 -5.75 -6.10 90.16 6.45 5.12 7.44 -25.79 5.67 1.81 10.96 -1.18 6.13 4.86 2.95 0.62 -0.96 3.67 -0.19
收入百分比 26,116.46 29,528.67 732.61 348.56 69.05 69.18 68.26 68.64 120.20 102.20 93.53 95.38 98.94 102.53 111.06 104.71 91.50 80.70 68.94 63.80
运营支出 513 560 606 653 1,037 1,226 1,305 1,419 1,275 1,403 1,432 1,522 1,476 1,410 1,440 1,433 1,479 1,554 1,628 1,700
改变 (%) 9.26 8.23 7.60 58.95 18.16 6.45 8.79 -10.14 9.99 2.11 6.28 -3.03 -4.47 2.11 -0.49 3.23 5.06 4.74 4.41
收入百分比 35,032.55 41,081.38 1,170.32 638.03 105.65 117.50 117.39 119.53 253.44 224.30 205.90 201.10 204.70 190.95 201.41 183.54 164.56 153.96 132.89 128.64
营业收入 -511 -559 -555 -550 -55 -183 -193 -232 -772 -777 -737 -765 -755 -672 -725 -652 -580 -545 -403 -378
改变 (%) 9.30 -0.78 -0.79 -89.93 229.25 5.88 19.99 232.97 0.68 -5.23 3.88 -1.34 -11.04 7.95 -10.04 -11.02 -6.15 -26.04 -6.08
收入百分比 -34,932.55 -40,981.38 -1,070.32 -538.03 -5.65 -17.50 -17.39 -19.53 -153.44 -124.30 -105.90 -101.10 -104.70 -90.95 -101.41 -83.54 -64.56 -53.96 -32.89 -28.64
利息花费 -1 -1 -1 -2 -3 -3 -3 -3 -7 -17 -26 -36 -41 -35 -30 -25 -25 -34 -42 -51
改变 (%) -3.15 24.14 19.45 49.03 4.96 30.07 -7.01 113.48 149.84 53.09 37.57 14.73 -14.50 -14.72 -15.94 0.07 33.79 24.68 19.95
收入百分比 -80.33 -83.50 -2.73 -1.65 -0.26 -0.25 -0.31 -0.27 -1.36 -2.73 -3.75 -4.74 -5.71 -4.77 -4.20 -3.23 -2.81 -3.35 -3.44 -3.83
净利 -1,853 -391 -329 -266 60 -65 -78 -296 -987 -887 -781 -867 -584 -631 -761 -471 -376 -441 -280 -209
改变 (%) -78.87 -16.02 -19.07 -122.41 -208.29 20.97 279.71 232.78 -10.14 -11.94 11.10 -32.72 8.17 20.59 -38.14 -20.26 17.34 -36.40 -25.47
收入百分比 -126,541.05 -28,694.65 -634.35 -260.11 6.07 -6.19 -7.03 -24.97 -196.06 -141.76 -112.23 -114.59 -80.93 -85.47 -106.47 -60.31 -41.77 -43.65 -22.88 -15.81

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista